Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Orlistat

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Orlistat. Displaying page 1 of 1.
    EudraCT Number: 2008-006986-10 Sponsor Protocol Number: W3680604 Start Date*: 2009-02-04
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
    Medical condition: Weight loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004797-79 Sponsor Protocol Number: W2660371 Start Date*: 2007-09-28
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
    Medical condition: Weight loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003320-40 Sponsor Protocol Number: EP-003 Start Date*: 2023-03-14
    Sponsor Name:Empros Pharma AB
    Full Title: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003395-22 Sponsor Protocol Number: W3600586 Start Date*: 2008-09-04
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: The Effects of Weight Reduction with Orlistat vs. Placebo on Changes in Body Composition
    Medical condition: Weight Loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002096-32 Sponsor Protocol Number: STH 14007 Start Date*: 2005-12-02
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A randomised controlled clinical trial of metformin versus orlistat for the management of obses anovulatory women
    Medical condition: Anovulatory Obese Women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001692-30 Sponsor Protocol Number: 003/07 Start Date*: 2009-11-06
    Sponsor Name:Certmedica International GmbH
    Full Title: monocentric randomised double-blind pilot trial, double dummy design for comparison of two therapy reginem formoline L112 vs. Orlistat 60 mg in patients with overweight or adipositas
    Medical condition: The product alli and the comparsion product fromoline L112 (medical device) decrease weight by influencing the fat absorption. The effects of both regimes should cause similar results in weight loss.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001055-50 Sponsor Protocol Number: EP-001 Start Date*: 2016-08-08
    Sponsor Name:Empros Pharma AB
    Full Title: A, single center, controlled, multiple dose, randomized study during two weeks, investigating the effect of the test formulation on efficacy, safety and markers for appetite regulation, glucose and...
    Medical condition: Obesity and diabetes, type 2.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000254-23 Sponsor Protocol Number: ATL 962/175/CL Start Date*: 2004-11-09
    Sponsor Name:Alizyme Therapeutics Limited
    Full Title: A Phase II Multicentre, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of ATL 962 to Assess Weight Loss, Safety and Tolerability in Obese Patients with Type II Diabetes being ...
    Medical condition: Treatment of obesity in patients with Type II diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004481-13 Sponsor Protocol Number: NN8022-1807 Start Date*: 2006-10-18
    Sponsor Name:Novo Nordisk A/S [...]
    1. Novo Nordisk A/S
    2. Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in obese subjects without diabetes A 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an o...
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    9.0 10012601 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) FI (Completed) DK (Completed) NL (Completed) BE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004866-15 Sponsor Protocol Number: EMI111963 Start Date*: 2008-12-18
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A Longitudinal MRI Study of Changes in Regional Body Composition During Orlistat (60mg)-Assisted Dieting
    Medical condition: Weight loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001661-91 Sponsor Protocol Number: ML19569 Start Date*: 2016-12-09
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents
    Medical condition: Obesity in combination with metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10058097 Metabolic disorder PT
    19.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2016-005248-41 Sponsor Protocol Number: DDD17Fenogal Start Date*: 2017-05-17
    Sponsor Name:KU Leuven - Drug Delivery and Disposition
    Full Title: Influence of gastrointestinal lipid digestion in the absorption of fenofibrate from a lipid-based formulation
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004545-32 Sponsor Protocol Number: EP-002 Start Date*: 2020-04-16
    Sponsor Name:Empros Pharma AB
    Full Title: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating th...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000763-23 Sponsor Protocol Number: ANJ900D3501 Start Date*: 2021-12-28
    Sponsor Name:Anji Pharma (US) LLC
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo- and Comparator-Controlled Study to Compare the Glycemic Effects, Safety, and Tolerability of Metformin Hydrochloride Delayed-Releas...
    Medical condition: Type 2 Diabetes Mellitus with varying renal function from normal up to CKD3B
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) BG (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004431-79 Sponsor Protocol Number: CC-90001-NASH-001 Start Date*: 2019-11-15
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSEFINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVE...
    Medical condition: Confirmed diagnosis of NASH and Stage 3 or Stage 4 fibrosis based upon the NASH Clinical Research Network (CRN) Histologic Scoring System and a nonalcoholic fatty liver disease (NAFLD) Activity Sco...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Ongoing) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:25:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA